Savara Inc. (SVRA)

Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Savara Inc. 

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Savara Inc. (“Savara” or “the Company”) (NYSE: SVRA). The investigation concerns whether Savara and certain of its officers and/or directors have violated federal securities laws.


On October 2, 2019, pre-market, Savara disclosed the response from a Type C meeting with the U.S. Food and Drug Administration (“FDA”) regarding the Company’s Molgradex development program for autoimmune pulmonary alveolar proteinosis (aPAP).  Specifically, Savara advised investors that “the FDA indicated that the data provided in the briefing package do not provide sufficient evidence of efficacy and safety and did not recommend that the Company submit a Biologics License Application (BLA).”  On this news, Savara’s stock price fell $1.45 per share, or 58.47%, to close at $1.03 per share on October 2, 2019.


If you are aware of any facts relating to this investigation, or purchased Savara shares, you can assist this investigation by contacting Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 


Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

© 2019 Bronstein, Gewirtz & Grossman, LLC

  • Twitter Social Icon

BG&G is not affiliated to any of these companies. All respective trademarks are owned by the respective companies.